SUNIL BADVE, M.D.
Medical Practice at Barnhill Dr, Indianapolis, IN
License number
Indiana 01055582A
Category
Medical Practice
Type
Clinical Pathology/Laboratory Medicine
Address
Address
635 Barnhill Dr, Indianapolis, IN 46202
Phone
(317) 274-4806
Personal information
See more information about SUNIL BADVE at radaris.comName
Address
Phone
8100 N Meridian St, Indianapolis, IN 46260
Indianapolis, IN
8100 Meridian St, Indianapolis, IN 46260
8100 N Meridian St, Indianapolis, IN 46260
Organization information
See more information about SUNIL BADVE at bizstanding.comSunil Badve MD
350 W 11 St, Indianapolis, IN 46202
Phone:
(317) 491-6484 (Phone)
Description:
There are 39 doctors at this site. Surgery is not performed at this site.
Sunil S. Badve
Professional information
Professor At Indiana University
Position:
Director, Translational Genomics Core lab at Indiana University School of Medicine, Professor at Indiana University
Location:
Indianapolis, Indiana Area
Industry:
Hospital & Health Care
Work:
Indiana University School of Medicine
since Apr 2008
-
Director, Translational Genomics Core lab
Indiana University
since Apr 2002
-
Professor
Northwestern Medical Faculty Foundation
Jul 1999 - Mar 2002
-
Assistant Professor
Education:
Grant Medical College 1978 - 1984
MBBS, MD
MBBS, MD
Dr. Sunil Badve, Indianapolis IN - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology, Clinical Pathology
Address:
IU Health Pathology Laboratory
350 W 11Th St SUITE 4010, Indianapolis 46202
(317) 491-6000 (Phone)
350 W 11Th St SUITE 4010, Indianapolis 46202
(317) 491-6000 (Phone)
Certifications:
Anatomic & Clinical Pathology, 1999
Awards:
Healthgrades Honor Roll
Languages:
English
Professor At Indiana University
Position:
Director, Translational Genomics Core lab at Indiana University School of Medicine, Professor at Indiana University
Location:
Indianapolis, Indiana Area
Industry:
Hospital & Health Care
Work:
Indiana University School of Medicine
since Apr 2008
-
Director, Translational Genomics Core lab
Indiana University
since Apr 2002
-
Professor
Northwestern Medical Faculty Foundation
Jul 1999 - Mar 2002
-
Assistant Professor
Education:
Grant Medical College 1978 - 1984
MBBS, MD
MBBS, MD
Sunil S Badve, Indianapolis IN
Specialties:
Pathologist
Address:
635 Barnhill Dr, Indianapolis, IN 46202
Education:
Doctor of Medicine*
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)*
Sunil S Badve, Indianapolis IN
Specialties:
Pathology, Anatomic Pathology, Clinical Pathology/Laboratory Medicine
Work:
Indiana University
350 W 11Th St, Indianapolis, IN 46202
350 W 11Th St, Indianapolis, IN 46202
Education:
Grant Medical College
Materials And Methods For Identifying Patients At Heighten Risk For Developing Her2+ Related Brain Tumors
US Patent:
2011026, Nov 3, 2011
Filed:
Nov 29, 2010
Appl. No.:
12/955217
Inventors:
Sunil Badve - Indianapolis IN, US
Lang Li - Carmel IN, US
George Sledge - Indianapolis IN, US
Renata Duchnowaska - Warsaw, PL
Jacek Jassem - Gdansk, PL
Patricia Steeg - Laurel MD, US
Lang Li - Carmel IN, US
George Sledge - Indianapolis IN, US
Renata Duchnowaska - Warsaw, PL
Jacek Jassem - Gdansk, PL
Patricia Steeg - Laurel MD, US
Assignee:
INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION - Indianapolis IN
International Classification:
C40B 30/04, G01N 33/574, C07K 16/22, C07K 16/32, C07K 16/40, C07K 16/18, C12Q 1/68, C07H 21/00
US Classification:
506 9, 435 611, 435 71, 536 2431, 5303877, 5303897, 5303892
Abstract:
Aspects of the invention include methods for identifying patients with HER2+ cancers that are at a heightened risk for developing brain metastasis within three years of having been diagnosed with HER2+ cancer. Some embodiments are methods that include the steps of contacting at least a portion of the tumor tissue from patients with probes that interact with the products of a set of thirteen genes that are expressed in these patients at markedly higher levels than in similarly situated patients that are not a heightened risk for developing brain metastasis within this three year window. In some embodiments the tissue samples are assayed from the presence of RNA indicative of the expression of member of a set of 13 genes identified as being differentially expressed in patients with and without a heightened risk for developing brain metastasis.
Materials And Methods For Diagnosing And Predicting The Course Of Prostate Cancer
US Patent:
2013020, Aug 8, 2013
Filed:
Jun 1, 2011
Appl. No.:
13/700777
Inventors:
Sunil Badve - Indianapolis IN, US
Harikrishna Nakshatri - Indianapolis IN, US
Harikrishna Nakshatri - Indianapolis IN, US
Assignee:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION - Indianapolis IN
International Classification:
G01N 33/68
US Classification:
424649, 435 71, 435 32, 435 612, 435 611
Abstract:
Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p
Cancer Therapy Prognosis
US Patent:
2010006, Mar 18, 2010
Filed:
Jan 30, 2008
Appl. No.:
12/524845
Inventors:
Sunil Badve - Indianapolis IN, US
Harikrishna Nakshatri - Zionsville IN, US
Harikrishna Nakshatri - Zionsville IN, US
Assignee:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION - Indianaplois IN
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Methods and compositions based on FOXA1 expression to predict long-term disease-free survival in patients with breast cancer are disclosed. In ER+ positive patients, expression of FOXA1 is useful in identifying a subgroup of patients with a better prognosis. FOXA1 expression correlates with luminal subtype breast cancer, and serves as a clinical marker for luminal subtype breast cancer. Expression of FOXA1 is useful as a prognostic marker for an effective response tumors and as a predictive marker for a greater likelihood of response to an anti-hormonal therapy. Prognostic ability of FOXA1 in low-risk breast cancers is useful in treatment decision making.